Cure8 research brief
Why This Matters
The report highlights a serious drug-related complication (pancytopenia/myelosuppression and hair loss) in a patient treated with azathioprine plus sulfasalazine for ulcerative colitis, suggesting clinicians and patients should be aware of rare but severe toxicity and consider careful blood monitoring.
Who Should Pay Attention
Adult patients with ulcerative colitis on azathioprine or sulfasalazine, gastroenterologists, IBD clinicians, and pharmacists
Study Snapshot
What To Know
A patient with ulcerative colitis developed marked pancytopenia and myelosuppression after treatment with azathioprine and sulfasalazine.
The authors note that significant thiopurine toxicity is often associated with TPMT or NUDT15 mutations, but in this report those enzyme tests were reportedly normal, suggesting that combined drug effects or interaction might have potentiated toxicity. The report also mentions alopecia totalis occurring alongside the myelosuppression.
The article appears to be a single-case report (abstract-level content provided), so it cannot establish how often this happens or prove causation; it raises a safety signal that may warrant clinician awareness and careful monitoring.
Keep In Mind
This classification and curator note are based on the article abstract/partial text (case report) provided; single-case reports indicate possible signals but cannot determine incidence or causation. TPMT and NUDT15 were reportedly normal in this case, so an interaction or other mechanism is suggested but unproven.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.